Updated on 7 October 2014
This is the seventh edition of the BioSpectrum Asia Pacific Bioscience Industry Survey
Singapore: The bioscience industry in the major markets of the Asia-Pacific region excluding Japan and comprising Australia, China, India, South Korea, Malaysia, Singapore, and Taiwan recorded a 12 percent growth in 2013. The total bioscience revenues in 2013 stood at $173.64 billion, compared to the $154.40 billion sales figure by end of December 2012. The industry's growth in 2013 was marginally higher at 12 percent compared to the previous year's growth of 11 percent. The growth has been driven by China, despite the Chinese pharma market encountering several changes. China registered 22 percent growth. Malaysia and Singapore also registered double digit growth of 12 percent and 48 percent respectively, while India, Australia, and South Korea witnessed low single digit growth.
• Public listed companies cross $100 billion mark for the first time
• Industry registers 12 percent growth
• Top 20 companies still account for nearly 60 percent market share
One of the main features of this year's survey is that all the players in the list of Top 20 companies have crossed the $1 billion sales revenue. This is good news as the number of billion dollar companies is swelling in Asia Pacific - as result of both organic growth and inorganic growth strategies via mergers, acquisitions, and joint ventures.